169 related articles for article (PubMed ID: 36438781)
1. Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation.
Minoux K; Lassailly G; Ningarhari M; Lubret H; El Amrani M; Canva V; Truant S; Mathurin P; Louvet A; Lebuffe G; Goria O; Nguyen-Khac E; Boleslawski E; Dharancy S
Transpl Int; 2022; 35():10569. PubMed ID: 36438781
[TBL] [Abstract][Full Text] [Related]
2. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.
Kulik L; Heimbach JK; Zaiem F; Almasri J; Prokop LJ; Wang Z; Murad MH; Mohammed K
Hepatology; 2018 Jan; 67(1):381-400. PubMed ID: 28859222
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation.
Lee SK; Jang JW; Nam H; Sung PS; Kim HY; Kwon JH; Lee SW; Song DS; Kim CW; Song MJ; Choi HJ; You YK; Bae SH; Choi JY; Yoon SK
Hepatol Int; 2021 Feb; 15(1):137-145. PubMed ID: 33496932
[TBL] [Abstract][Full Text] [Related]
4. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
Hoffmann K; Ganten T; Gotthardtp D; Radeleff B; Settmacher U; Kollmar O; Nadalin S; Karapanagiotou-Schenkel I; von Kalle C; Jäger D; Büchler MW; Schemmer P
BMC Cancer; 2015 May; 15():392. PubMed ID: 25957784
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis.
Li Z; Gao J; Zheng S; Wang Y; Xiang X; Cheng Q; Zhu J
Turk J Gastroenterol; 2021 Jan; 32(1):30-41. PubMed ID: 33893764
[TBL] [Abstract][Full Text] [Related]
6. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.
Firl DJ; Kimura S; McVey J; Hashimoto K; Yeh H; Miller CM; Markmann JF; Sasaki K; Aucejo FN
Hepatology; 2018 Oct; 68(4):1448-1458. PubMed ID: 29604231
[TBL] [Abstract][Full Text] [Related]
7. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation.
Eilard MS; Andersson M; Naredi P; Geronymakis C; Lindnér P; Cahlin C; Bennet W; Rizell M
BMC Cancer; 2019 Jun; 19(1):568. PubMed ID: 31185950
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.
Waghray A; Balci B; El-Gazzaz G; Kim R; Pelley R; Narayanan Menon KV; Estfan B; Romero-Marrero C; Aucejo F
Clin Transplant; 2013; 27(4):555-61. PubMed ID: 23758296
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study.
Iavarone M; Invernizzi F; Ivanics T; Mazza S; Zavaglia C; Sanduzzi-Zamparelli M; Fraile-López M; Czauderna C; Di Costanzo G; Bhoori S; Pinter M; Manini MA; Amaddeo G; Yunquera AF; Piñero F; Blanco Rodríguez MJ; Anders M; Aballay Soteras G; Villadsen GE; Yoon PD; Cesarini L; Díaz-González Á; González-Diéguez ML; Tortora R; Weinmann A; Mazzaferro V; Romero Cristóbal M; Crespo G; Regnault H; De Giorgio M; Varela M; Prince R; Scudeller L; Donato MF; Wörns MA; Bruix J; Sapisochin G; Lampertico P; Reig M
Liver Transpl; 2021 Dec; 27(12):1767-1778. PubMed ID: 34388851
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence.
Jung DH; Tak E; Hwang S; Song GW; Ahn CS; Kim KH; Moon DB; Ha TY; Park GC; Ryoo BY; Lee KJ; Kim N; Kwon JH; Jwa EK; Lee SG
Liver Transpl; 2018 Jul; 24(7):932-945. PubMed ID: 29710388
[TBL] [Abstract][Full Text] [Related]
11. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
Lee DD; Samoylova M; Mehta N; Musto KR; Roberts JP; Yao FY; Harnois DM
Liver Transpl; 2019 Feb; 25(2):228-241. PubMed ID: 30198150
[TBL] [Abstract][Full Text] [Related]
12. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.
Vitale A; Volk ML; Pastorelli D; Lonardi S; Farinati F; Burra P; Angeli P; Cillo U
Hepatology; 2010 Jan; 51(1):165-73. PubMed ID: 19877181
[TBL] [Abstract][Full Text] [Related]
13. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments.
Tovoli F; Pallotta DP; Sansone V; Iavarone M; De Giorgio M; Ielasi L; Di Costanzo GG; Giuffrida P; Sacco R; Pressiani T; Di Donato MF; Trevisani F; Fagiuoli S; Piscaglia F; Granito A
Transplantation; 2023 Jan; 107(1):156-161. PubMed ID: 35996072
[TBL] [Abstract][Full Text] [Related]
15. Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation.
Schmitz S; Lurje G; Ulmer F; Andert A; Bruners P; Schulze-Hagen M; Neumann U; Schoening W
Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):228-236. PubMed ID: 30718181
[TBL] [Abstract][Full Text] [Related]
16. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis.
Lee MW; Raman SS; Asvadi NH; Siripongsakun S; Hicks RM; Chen J; Worakitsitisatorn A; McWilliams J; Tong MJ; Finn RS; Agopian VG; Busuttil RW; Lu DSK
Hepatology; 2017 Jun; 65(6):1979-1990. PubMed ID: 28170115
[TBL] [Abstract][Full Text] [Related]
17. Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma.
Antwi SO; Habboush YY; Chase LA; Lee DD; Patel T
Ann Hepatol; 2018 Oct; 17(6):969-979. PubMed ID: 30600299
[TBL] [Abstract][Full Text] [Related]
18. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a report of four cases.
Hong YM; Yoon KT; Cho M; Kang DH; Kim HW; Choi CW; Park SB; Heo J; Woo HY; Lim W
Korean J Gastroenterol; 2015 Apr; 65(4):246-51. PubMed ID: 25896160
[TBL] [Abstract][Full Text] [Related]
20. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.
Pompili M; Francica G; Ponziani FR; Iezzi R; Avolio AW
World J Gastroenterol; 2013 Nov; 19(43):7515-30. PubMed ID: 24282343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]